[Skip to Content]
[Skip to Content Landing]
Views 231
Citations 0
Correction
May 2019

Incorrect Author Affiliation

JAMA Oncol. 2019;5(5):745. doi:10.1001/jamaoncol.2019.1384

In the Original Investigation titled “Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial,”1 published online only on April 12, 2018, an incorrect affiliation was reported for author Giulia Siravegna, PhD. Dr Siravegna’s correct affiliations are Candiolo Cancer Institute–FPO, IRCCS, Candiolo, Torino, Italy, and University of Torino, School of Medicine, Torino, Italy. The article has been corrected online.

References
1.
Montagut  C, Argilés  G, Ciardiello  F,  et al.  Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA analyses: a phase 2 randomized clinical trial.  JAMA Oncol. 2018;4(4):e175245. doi:10.1001/jamaoncol.2017.5245PubMedGoogle ScholarCrossref
×